Chronic Myeloid Leukemia
Springer International Publishing (Verlag)
978-3-030-71915-9 (ISBN)
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.
lt;p>Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany.
Founder and Chair, European LeukemiaNet (ELN)
Founder and chair of the German CML Study Group 1982-2017
Former Secretary General
International Association of Comparative Research on Leukemia & Related Diseases (IACRLRD)
Former Chief of Medicine, Dean & President
German Society of Hematology and Oncology
Honorary member of the Polish and German Societies for Hematology and Oncology
Current focus: promotion of cooperative research for curing leukemia
Cytogenetics of Chronic Myeloid Leukemia (CML).- The Biology and Pathogenesis of Chronic Myeloid Leukaemia.- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy.- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors.- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update.- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death.- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia.- The Role of Hematopoietic Stem Cell Transplantation in CML.- CML end-phase and blast crisis: implications and management.- The Interferon-alpha Revival in CML.- Managing Pregnancy in Chronic Myeloid Leukemia.- Response-Related Predictors of Survival and of Treatment Free Remission in CML.- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response.
| Erscheinungsdatum | 08.06.2022 |
|---|---|
| Reihe/Serie | Hematologic Malignancies |
| Zusatzinfo | IX, 273 p. 42 illus., 35 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Gewicht | 544 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Schlagworte | BCR-ABL • Chronic myeloid leukaemia • Deep molecular response • fertility • Health Economics • hematopoietic stem cell transplantation • Imatinib resistance • Interferon-alpha • Philadelphia chromosome • Survival • tyrosine kinase inhibitors |
| ISBN-10 | 3-030-71915-4 / 3030719154 |
| ISBN-13 | 978-3-030-71915-9 / 9783030719159 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
